

## ERS 2022 WORKING GROUP MEETING MINUTES: COPD

Meeting details		
Meeting location	Hotel SB Plaza Europa (Barcelona Room) + MS Teams online	
Meeting date	Saturday 3 <sup>rd</sup> September 2022	
Meeting time	12:00 CET	
Chair(s)	Marc Miravitlles	
Attendees	Andrei Malinovschi Nicolas Roche Chin Kook Rhee Bernardino Alcazar Navarrete Joan Soriano Dermont Ryan	Sean Loh Pietro Pirina Ronald Dandurand Therese Lapperre Marc Miravitlles Valeria Perugini Graham Lough Michael Walker
Objectives		
1	Update on active projects	
2	Future projects	

Items		
Update on current projects	Assessing the utility of peak inspiratory flow (PIF) in predicting COPD exacerbations (PI: Omar Usmani)  Marc has given an update on the project while informing the members of the WG on the successful completion of the patient recruitment last August. 19 study sites have actively enrolled 416/400 and are now continuing to monitoring activities (e.g., 1st and 2nd FU visits). The WG members have also discussed about the publication of a manuscript on the baseline characteristics which is planned to be submitted by end of 2022.  Chin Kook has mentioned that PIF measurements may be different in Asian patients from those collected by other partners and thus it could be of interest in publishing these results in a distinct paper.	
Future projects	PREdicting the risk for first COPD severe exacerbation (PRECISE- X) (proposed by Bernardino Alcazar Navarrete).  Bernardino has initially explained the aim of this database study which is to design a population-based risk prediction model for the first severe COPD exacerbation using variables captured routinely in electronic	

Respiratory Effectiveness Group, ESpace North, 181 Wisbech Road, Littleport, Ely, Cambridgeshire, CB6 1RA, UK enquiries@effectivenessevaluation.org | effectivenessevaluation.org



healthcare record data. He has then mentioned that a full protocol and budget of this have now been finalised and will soon be submitted to AZ as AZ have shown interest in financially supporting the study. He has also reported that AZ is likely intended to fund the second phase of the study which is about the validation of the model by performing an extra validation study in at least one other database/international cohort (e.g., SIDIAP) to calibrate in a different population and healthcare system. It was noted that other databases could be explored as well (France, Netherlands, etc)

Effects of triple pharmacological therapy on post-discharge outcomes in patients with COPD (proposed by Chin Kook Rhee).

Chin Kook has introduced the new project while explaining the main object of this: "To identify patients at most risk of being readmitted to hospital, with a specific focus on the risk/benefit ratio of triple therapy on an individual patient basis in short-term follow-up periods".

A full proposal and budget have already been prepared and approved by the steering committee. During the WG meeting, the members have actively discussed on the project while defining new aspects and notions to be considered for the preparation of a protocol as soon as a pharmaceutic company/ies will decide funding the project. Currently, the proposal has been sent to distinct companies that are internally evaluated the study.

There is also a proposal to include a discharge bundle to standardise as much as possible the care of patients after discharge